NCT06870435View on ClinicalTrials.gov

Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas

NARecruitingINTERVENTIONAL
Enrollment

68,649

Participants

Timeline

Start Date

January 24, 2025

Primary Completion Date

January 23, 2026

Study Completion Date

December 31, 2035

Conditions
Nasopharyngeal Carcinoma (NPC)ScreeningEpstein Barr Virus
Interventions
BIOLOGICAL

Blood, nasopharyngeal swab and saliva

Collect blood, nasopharyngeal swab and saliva samples from participants.

DIAGNOSTIC_TEST

EBNA1-IgA, VCA-IgA, P85-Ab and EBV DNA

Detect EBNA1-IgA, VCA-IgA, P85-Ab and EBV DNA for all participants.

DIAGNOSTIC_TEST

Novel screening biomarkers

Next-generation sequencing for EBV and castoff cells using nasopharyngeal swabs, etc..

DIAGNOSTIC_TEST

Endoscopic examinations with or without biopsy

High-risk participants will refer to endoscopic examinations with or without biopsy

Trial Locations (1)

519000

RECRUITING

The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai

All Listed Sponsors
lead

Ming-Yuan Chen

OTHER